Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfaphenazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 14/20 | 1.00 |
| ▸ | CYP2C18 | P33260 | 7/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 7/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | OXTR | P30559 | 3/20 | 0.57 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfaphenazole SCHEMBL28086445 | 0.89 | CYP2C9 (0.80) | CYP2C9CYP2C18CYP2C19LMNAPOLB | |
| Sulfaphenazole SCHEMBL13723748 | 0.88 | CYP2C9 (0.77) | CYP2C9CYP2C18CYP2C19LMNAPOLB | |
| Sulfaphenazole SCHEMBL14837290 | 0.87 | CYP2C9 (0.75) | CYP2C9CYP2C18CYP2C19LMNAPOLB | |
| SCHEMBL3849522 | 0.86 | CYP2C9 (0.81) | CYP2C9CYP2C18CYP2C19LMNAPOLB | |
| SCHEMBL11267272 | 0.85 | CYP2C9 (0.77) | CYP2C9CYP2C18CYP2C19LMNAPOLB | |
| SCHEMBL5450995 | 0.84 | CYP2C9 (0.78) | CYP2C9CYP2C18CYP2C19LMNAPOLB | |
| Sulfaphenazole SCHEMBL20770004 | 0.84 | CYP2C9 (0.71) | CYP2C9CYP2C18CYP2C19LMNAPOLB | |
| SCHEMBL3845328 | 0.83 | CYP2C9 (0.75) | CYP2C9CYP2C18CYP2C19LMNAPOLB | |
| SCHEMBL3849178 | 0.81 | CYP2C9 (0.71) | CYP2C9CYP2C18CYP2C19LMNAPOLB | |
| SCHEMBL3851318 | 0.80 | CYP2C9 (1.00) | CYP2C9CYP2C18CYP2C19LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4326 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| EP-4694929-A1 | METHODS FOR TREATING CORNEAL INJURIES | Lin, Sung-Jan (TW) | 2026-02-18 | — | — | EP | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4637829-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER | Cellis Sp. z o.o. ([Ltd.] (PL) | 2025-10-29 | — | — | EP | claimed |
| EP-4587062-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | Cellis AG (CH) | 2025-07-23 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4536217-A1 | CO-AGENTS AS THERAPY AGAINST ANAEROBIC PATHOGENS | Fleurir Abx LLC (US) | 2025-04-16 | — | — | EP | claimed |
| US-20250099557-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) | 2025-03-27 | — | — | US | claimed |
| US-20250075182-A1 | CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM | CELLIS AG (CH) | 2025-03-06 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| EP-0572560-A4 | USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY. | SHAPIRO HOWARD K (US) | 1995-04-26 | — | — | EP | claimed |
| EP-0572560-A1 | USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO, Howard, K. (US) | 1993-12-08 | — | — | EP | claimed |
| WO-1992014456-A1 | USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 1992-09-03 | — | — | WO | claimed |
| EP-0220243-B1 | METHOD FOR DETERMINING COHESION IN STAPLE FIBERS | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1989-01-25 | — | — | EP | claimed |
| US-4599416-A | Process for the preparation of aqueous solutions of potentiated sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1986-07-08 | — | — | US | claimed |
| US-4532245-A | Pharmaceutical compositions | HOFFMANN-LA ROCHE INC. (US) | 1985-07-30 | — | — | US | claimed |
| US-4315931-A | MICROBIOCIDES, INFECTIOUS DISEASES | BASF AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | claimed |